Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Approves Lirafugratinib for Advanced Bile Duct Cancer

25 September 2026 · By · Wire by Fusion42

Published

25 September 2026

Topic

opportunities

◆ Sectors

Drug Discovery

◆ Geography

United States

◆ Source

Read at labroots.com →

◆ Verified

Fusion42 · 25 September 2026 · Fusion42 review

The FDA has approved lirafugratinib for the treatment of advanced bile duct cancer, providing a new therapeutic option for patients with this difficult-to-treat disease.

This Wire brief sits within Fusion42's coverage of Drug Discovery, and 10 sources have reported it between 16 Sep 2026 and 5 Oct 2026.

◆ ◆ The Wire takeaway

You now have a newly approved FDA therapy for advanced bile duct cancer to consider integrating into your pipeline or service offerings. This shifts patient treatment possibilities and opens the US market for therapies targeting this cancer type.

◆ Coverage

10 sources · first reported 16 Sep 2026 · latest 5 Oct 2026

◆ Topics

Drug Discoverydrug-approvalcancer-therapyFDAbile-duct-canceroncology